Top 10 at 10: James Hardie delivers super strong quarter; Auris digs up more gold

Getty Images
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.
WINNERS
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
• Small mining outfit Auris Minerals (ASX:AUR) has returned “significant results” from its drilling of gold and base metals at the Morck Well project in WA, specifically at the Jacques East prospect.
Highlights? High-grade gold results: 15m @ 4.11g/t Au from 35m including 4m @ 12.8g/t Au from 38m; 10m @ 1.49g/t Au from 45m; and high-grade, supergene gold mineralisation at Jacques East defined over 70m laterally on section, remaining open along strike to northeast and southwest for up to 400m.
• Fibre cement gun James Hardie (ASX:JHX) has delivered a strong first quarter ending June 30. In fact, it’s the company’s best ever first quarter results for both Adjusted Net Income and Operating Cash Flow.
It’s talking:
• Global net sales of US$954.3 million
• Record global adjusted EBITDA of US$279.1 million, with an adjusted EBITDA margin of 29.2%
• Record global adjusted EBIT of US$234.2 million, with an adjusted EBIT margin of 24.5%
• Adjusted net income of US$174.5 million, up 13%
• Adjusted diluted EPS of US$0.39 per share, up 14%
• Operating cash flow increased 64% to US$252.3 million
• WT Financial Group (ASX:WTL) – as the name suggests, a financial services group – is up on its full-year indicative results for FY2023. It’s positive, with the headline being revenue and other income up 57% over the prior period to $162.49m (FY22 $103.63). Also, it’s seen a more than doubling of both net profit before tax (NPBT) – up 115% to $5.04m (FY22 $2.35m); and net profit after tax (NPAT) – up 130% to $4.31m (FY22 $1.87m).
• Recce Pharmaceuticals (ASX:RCE) is advancing its testing of RECCE 327 Gel (R327G) through a Therapeutic Goods Administration Special Access Scheme. The drug is designed (but not as yet market approved) for patients suffering antibiotic-resistant Gram-positive and Gram-negative bacterial infections. A positive clinical response has so far been indicated.
LOSERS
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Related Topics
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.